Edition:
India

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

7.69CAD
2:29am IST
Change (% chg)

$0.06 (+0.79%)
Prev Close
$7.63
Open
$7.65
Day's High
$7.71
Day's Low
$7.62
Volume
282,438
Avg. Vol
187,651
52-wk High
$11.00
52-wk Low
$7.51

Summary

Name Age Since Current Position

Samira Sakhia

2016 President, Director

Jonathan Goodman

48 2013 Chief Executive Officer, Director

Jeffrey Kadanoff

46 Chief Financial Officer

Amal Khouri

Vice President - Business Development

Meir Jakobsohn

2015 Director

Sarit Assouline

2017 Independent Director

James Gale

67 2013 Independent Director

Robert Lande

53 2013 Independent Director

Sylvie Tendler

2014 Independent Director

Biographies

Name Description

Samira Sakhia

Ms. Samira Sakhia is President, Director of the Company. Prior to Knight, Ms. Sakhia served as the CFO at Paladin from 2001 to 2015. At Paladin, Ms. Sakhia was responsible for the finance, operations, human resources and investor relations functions. During her employment with Paladin, Ms. Sakhia was instrumental in executing in-licensing and acquisition transactions of Canadian and international pharmaceutical products and businesses. In addition, Ms. Sakhia led several M&A and strategic lending transactions as well as equity rounds on the Toronto Stock Exchange (“TSX”) and completed the sale of Paladin to Endo International for $3.2 billion. Ms. Sakhia currently serves of on the board of directors of Antibe Therapeutics Inc., Crescita Therapeutics Inc., Nuvo Pharmaceuticals Inc. and Profound Medical Corp. Ms. Sakhia holds an M.B.A. and a Bachelors of Commerce degree from McGill University, and is also a Chartered Professional Accountant.

Jonathan Goodman

Mr. Jonathan Ross Goodman is Chief Executive Officer, Director of the Company. Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin which was acquired by Endo Health Solutions Inc. for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later. Prior to co-founding Paladin in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman currently serves on the board of directors of Medimetriks Pharmaceuticals, Inc. and Medison Biotech (1995) Ltd. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University.

Jeffrey Kadanoff

Mr. Jeffrey Kadanoff is Chief Financial Officer of the Company. He is Vice President-Strategic Planning and Development, Reitmans (Canada) Limited from 2011-2013.

Amal Khouri

Ms. Amal Khouri is Vice President - Business Development of the Company. Global Business Development and Licensing, Novartis Pharmaceuticals Corporation from 2007-2014.

Meir Jakobsohn

Mr. Meir Jakobsohn is Director of the Company. Mr. Jakobsohn is the CEO of Israeli-based Medison Pharma Ltd. (“Medison”) which he founded in 1996 and spearheaded to becoming a leading international marketing group. Formerly, he served as the Chief Operating Officer of M. Jakobsohn Ltd., a pioneer in opening the Israeli market to global pharmaceutical companies like Ciba-Geigy (Novartis), which it represented between 1937 and 1995. Mr. Jakobsohn holds a B.A. in Economics from Bar-Ilan University and an Executive M.B.A. from Bradford University in the UK.

Sarit Assouline

Dr. Sarit Assouline is Director of the Company. Dr. Assouline is the Director of the Chronic Myelogenous Leukemia Clinic of the Jewish General Hospital and, in this capacity, has contributed to epidemiological research into the outcome of patients treated with tyrosine kinase inhibitors. Following her training in hematology and oncology at McGill University, Dr. Assouline completed a Master’s program in clinical epidemiology and biostatistics at McGill University, and a CIHR funded drug development fellowship at the National Cancer Institute of Canada Clinical Trials Group. Since 2005, she has been involved in the design and conduct of numerous clinical trials testing novel therapies in patients with leukemia and lymphoma. These therapies include novel targeted monoclonal antibody therapies, proteasome inhibitors, histone deacetylase inhibitors, and drugs targeting protein translation.

James Gale

Mr. James C. Gale is Independent Director of the Company. Mr. Gale is the founding partner of Signet Healthcare Partners (“Signet”). He is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent Inc., and also serves on the Board of Directors of Spepharm BV, Bionpharma Inc., CoreRx, Inc., Leon Nanodrugs GmbH, Pharmaceutics International, Inc. and Chr. Olesen Synthesis A/S. Prior to Signet, Mr. Gale worked for Gruntal & Co., LLC (“Gruntal”) as head of principal investment activities and investment banking. Prior to joining Gruntal, he worked for Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co. Mr. Gale holds an M.B.A. from the University of Chicago. Mr. Gale was on the Board of Paladin from 2008 to 2014.

Robert Lande

Mr. Robert N. Lande is Independent Director of the Company. Mr. Lande is the Chief Financial Officer of FXCM, Inc. a foreign exchange brokerage firm. Formerly, he was managing partner and Chief Operating Officer of Riveredge Capital Partners LLC (“Riveredge”). Prior to Riveredge, Mr. Lande worked for over 16 years within the BCE/Bell Canada group where his last position was Chief Financial Officer of Telecom Américas Ltd., a joint venture between Bell Canada International, AT&T (then SBC Communications) and America Movil. Mr. Lande is a chartered financial analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University. Mr. Lande was on the board of directors of Paladin from 1995 to 2014.

Sylvie Tendler

Ms. Sylvie Tendler is Independent Director of the Company. Sylvie Tendler is a leading pharmaceutical market research specialist. In 2001, she founded The Tendler Group, a custom medical marketing research company, which served 12 of the Top 20 global pharmaceutical companies. In 2007, the company was acquired by IntrinsiQ LLC (owned at the time by Accel-KKR). Ms. Tendler stayed through 2010 to oversee the managerial transition following the acquisition. Ms. Tendler has hands-on experience conducting global primary research in Canada, the U.S., the top 5 EU markets, as well as Brazil and Mexico, and has been involved in the development and launch of blockbuster prescription products across several therapeutic categories. Ms. Tendler holds a Master’s degree in International Management from the University of Maryland, and a Financial Management Certificate from Cornell University.

Basic Compensation

Name Fiscal Year Total

Samira Sakhia

1,244,150

Jonathan Goodman

429,156

Jeffrey Kadanoff

291,480

Amal Khouri

290,250

Meir Jakobsohn

--

Sarit Assouline

--

James Gale

--

Robert Lande

--

Sylvie Tendler

--
As Of  31 Dec 2016